Kick start day two with clinical case study reviews, group discussion forums, and new updates on the full end-to-end drug development landscape for allogeneic cell therapies.  

Leaders from; AgenTusBone TherapeuticsBristol Myers Squibb and TCR2 will be showcasing: 

  • Novel strategies to overcome safety and tolerability risks 
  • Processes to achieve reproducibility and comparability in manufacture  
  • Experience navigating global regulatory challenges for off-the-shelf production 

… and much more! 

Key speakers include:  

Joe Newell

COO

Atara Biotherapeutics

Peggy Sotiropoulou

Head of Research & Development

Celyad Oncology

Sumiti Jain

Director, Immuno- Oncology, Cell Therapy

Poseida Therapeutics

Tony Ho

EVP, Head of Research & Development

CRISPR Therapeutics

9:30 am Virtual Coffee Networking Rooms

10:00 am Chair’s Opening Remarks

Keynote Clinical Case Studies

10:05 am Realizing the Clinical Potential of CRISPR/Cas9 for Best-in-Class Allogeneic Therapies

  • Tony Ho EVP, Head of Research & Development, CRISPR Therapeutics

Synopsis

• Showcase clinical data from CTX110, CTX120 and CTX130 to review how allogeneic cells function in vivo
• Analayze depth of response, persistence and durability of the allogeneic cells to achieve complete responses
• How do allogeneic cells perform compared to autologous cell therapies?

10:35 am Learnings from Allogeneic CAR-T Clinical Trials

Synopsis

• Discussing patient conditioning without biologic immuno-depletion
• Outlining dosing considerations
• Evaluating cell expansion, persistence, and durability of response

11:05 am Differentiated Non-Gene Edited Technologies to Generate Off-The-Shelf CAR-T Cells for the Treatment of Hematopoietic and Solid Malignancies

Synopsis

• Leveraging non-gene edited technologies to disrupt TCR signaling to generate allogeneic CAR T cells
• Exploiting natural receptor/ligand interactions for CAR T cell therapy of metastatic colorectal cancer
• Discussing the first-in-class shRNA-based BCMA-targeting allogeneic CAR T candidate for the treatment of multiple myeloma

11:35 am Tech Slam

Synopsis

Quickfire 10-minute presentations from the leading solution providers in the space.

12:05 pm Refreshment Break

Synopsis

Take this time to follow up with your new connections with a 1-1 or group video call or take a break and make a coffee!

2:10 pm Speaker Breakout Discussions

Synopsis

The speakers of the previous session will join the speaker break out room where you can meet them, ask any further questions you might have and continue the conversation.

2:25 pm Refreshment Break

3.00PM Roundtable Discussion Session

Rob Igarashi, VP, Discovery & Pre-clinical Development, Kiadis Pharma

Re-Dosing to Increase Exposure Time
• Discuss whether the lifespan and exposure time to the tumor is critical to achieve efficacy
• Explore repeat dosing regimens to increase durability of response
• Question how to overcome the tolerability of redosing with frail patients, is there alternative approaches to multiple lymphodepletion regimes, or alternative gene editing methods to allow for cells to be repeatedly administered?

Innate Vs. Adaptive Immune Cell Types for Allogeneic Therapy
• Assess the different characteristics of NK, GDT and T cells and how this can impact their success as an allogeneic therapy
• Discuss current clinical and preclinical results, specifically assessing the potential to persist and safety profiles

4:45 pm Closing Remarks

4:50 pm Speaker Breakout Discussions

Synopsis

The speakers of the previous session will join the speaker break out room where you can meet them, ask any further questions you might have and continue the conversation.

5:05 pm Close of Conference